Tyra Biosciences, Inc.

Tyra Biosciences has recorded zero cyber incidents and zero material red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, low signal in our immediate window does not mean low risk; biotech companies face persistent pressures from equity dilution, financing cycles, and clinical trial dependencies that require deeper historical context. The full $49 Report expands analysis to 12 months of SEC filings, calculates dilution risk scores, maps financing history and runway, and flags AI-detected risk signals across officer changes and regulatory shifts. The full $49 Report adds comprehensive dilution scoring, 12-month filing context, financing trajectory analysis, and machine-detected risk signals that shape long-term shareholder value.